BioMap
BioMap builds xTrimo V4, a 268-billion-parameter foundation model for life sciences, and BioMap OS, a closed-loop AI discovery platform, licensed to and used by multinational pharmaceutical companies for antibody, protein, and therapeutic target discovery.
- Company typePrivate
- Founded2019
- HeadquartersPalo Alto, United States
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What BioMap does
BioMap is a life sciences AI company that builds foundation models and a closed-loop discovery platform for biopharmaceutical R&D. Its core asset is xTrimo V4, a 268-billion-parameter foundation model trained on multi-modal biological data spanning DNA, RNA, proteins, cells, chemistry, multi-cells, and biosystems, and positioned by the company as the first foundation model purpose-built for decoding biological systems. BioMap commercializes this capability through BioMap OS, a dry-wet closed-loop life science discovery system that integrates knowledge aggregation, predictive design, experimental control, and model training, and is deployable as standalone models, software, or full systems in cloud or on-premises configurations. The platform targets four verticals: antibody and protein discovery, innovative therapies and precision medicine, synthetic biology, and frontier scientific research. Validated use cases include de novo protein design, multi-objective optimization with precise epitope control, and AI-driven target identification.
BioMap operates as an enterprise B2B company serving multinational corporations, Fortune Global 500 companies, and industry leaders, with reported traction of 800+ institutional users, 30+ leading enterprise customers, 60+ proof-of-concept programs, and 40+ delivered antibody and protein programs. Revenue is generated through two channels: system licensing of BioMap OS (and underlying xTrimo components) for independent client workflows, and BioMap-conducted discovery services covering antibody discovery, protein discovery, and other specialized life science programs. Pricing is custom and not publicly disclosed. The company has secured named partnerships at the flagship tier (Sanofi for AI-driven drug discovery) and a strategic joint venture at the core tier (MegaStream TechBio with Harbour BioMed) that integrates xTrimo into a dedicated biologics pipeline business. The company was founded in 2019 by Baidu founder Robin Li and former Baidu Ventures CEO Liu Wei, is incorporated in China with operating presence in Palo Alto, and has filed confidentially for a Hong Kong IPO targeting a raise of several hundred million US dollars.
BioMap firmographics
Firmographics- Name
- BioMap
- Legal name
- BioMap
- Website
- https://biomap.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- BioMap builds xTrimo V4, a 268-billion-parameter foundation model for life sciences, and BioMap OS, a closed-loop AI discovery platform, licensed to and used by multinational pharmaceutical companies for antibody, protein, and therapeutic target discovery.
- Ownership category
- akta.pro rank
BioMap industry classification
Industry- Product category
- AI Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)
Keywords
Where BioMap is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Markets served
BioMap business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Revenue model
- System Licensing: BioMap OS can be deployed as models, software, or a complete system with configurable professional components, supporting cloud and on-premises deployment. This represents the primary commercial licensing model.
- Discovery Services: System-based discovery services including protein discovery and antibody discovery, where BioMap conducts discovery on behalf of clients in areas such as antibody and protein, innovative therapies and precision medicine, synthetic biology, and frontier scientific research.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
BioMap product offering
Product offeringCore offering
BioMap builds and licenses AI foundation models and an integrated life science discovery platform (BioMap OS) powered by the proprietary 268-billion-parameter xTrimo V4 foundation model. The platform delivers a dry-wet closed-loop discovery system for protein and antibody design, novel target identification, and therapeutic discovery, with both licensing and fee-based discovery services for enterprise pharmaceutical and biotech customers.
Product overview
BioMap offers a unified platform architecture centered on BioMap OS, an AI-driven life science discovery system powered by the xTrimo V4 foundation model (268 billion parameters). The platform provides modular functionality including knowledge aggregation, predictive design, experimental control, and model training, with deployment options as models, software, or complete systems. BioMap OS serves four verticals: antibody and protein discovery, innovative therapies and precision medicine, synthetic biology, and frontier scientific research, with configurable professional components supporting both cloud and on-premises deployment.
Differentiator
Problem solved
Functional benefit
Brands
- xTrimo: BioMap's 268-billion-parameter life science foundation model for decoding biological systems, achieving 300+ state-of-the-art performances across 20+ fields.
- BioMap OS
- MegaStream TechBio
Products and services
- BioMap OS AI-driven intelligent R&D platform powered by xTrimo foundation models, providing a dry-wet closed-loop life science discovery system that integrates knowledge aggregation, predictive design, experimental control, and model training for enterprise pharmaceutical and biotech customers conducting antibody/protein discovery, innovative therapies, synthetic biology, and frontier scientific research.
- xTrimo V4 Foundation Model World's first 268-billion-parameter life science foundation model that demonstrates cross-modal reasoning across DNA, RNA, proteins, cells, chemistry, multi-cells, and biosystems, achieving 300+ state-of-the-art model performances across 20+ fields, available for licensing as part of the BioMap OS offering to enterprise customers.
- System-Based Discovery Services Fee-based discovery services offered by BioMap to enterprise clients, including protein discovery and antibody discovery, where BioMap conducts discovery on behalf of clients in areas such as antibody and protein, innovative therapies and precision medicine, synthetic biology, and frontier scientific research using the BioMap OS platform.
Quantifiable outcome
- 300+ State-of-the-Art model performances across 20+ fields
- +3 more outcomes
Companies that use BioMap
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles1 record
BioMap technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature3 records
BioMap partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and flagship.
- Harbour BioMedcoreLong-term strategic partnership to jointly launch MegaStream TechBio, an AI-native pipeline company focused on complex biologics drug discovery. MegaStream combines Harbour BioMed's fully human antibody platform (Harbour Mice) and clinical development capabilities with BioMap's xTrimo foundation models. The entity prioritizes First-in-Class and Best-in-Class assets across cardiovascular, renal, oncology, and anti-aging areas, with projected 500%+ efficiency gains and 5+ petabytes of data generation within five years.
- SanofiflagshipBioMap previously partnered with French drugmaker Sanofi for AI-driven drug discovery applications utilizing the xTrimo foundation models. Sanofi has articulated a comprehensive strategy to become the first biopharma company powered by AI at scale.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
BioMap competitors and assessment
Company assessmentDirect peers
- Insitro: Insitro applies machine learning to drug discovery and development using large biological datasets and predictive models. Directly comparable to BioMap as an AI-native drug discovery platform serving enterprise pharma customers.
- Recursion Pharmaceuticals: Recursion combines high-throughput wet-lab biology with AI/ML to discover and develop therapeutics at scale. Comparable closed-loop AI+wet-lab model architecture and similar enterprise pharma partnership model.
- Schrödinger, Inc. Schrödinger provides computational chemistry and physics-based simulation software for drug discovery, including AI/ML-augmented platforms. Comparable as an enterprise-licensed AI/ML platform for life science discovery serving top pharma customers.
- Exscientia: Exscientia is an AI-driven precision medicine company using foundation model-like approaches for end-to-end drug discovery. Direct competitor in AI-native pharma discovery partnerships.
- Generate Biomedicines: Generate Biomedicines builds generative AI foundation models for protein design and biologics discovery. Highly comparable as a foundation-model-first AI biotech with similar antibody/protein design focus.
- AbCellera Biologics: AbCellera combines high-throughput antibody discovery platforms with AI/ML data analysis to discover biologics. Comparable enterprise-pharma partnership model and antibody-focused discovery pipeline.
- Iambic Therapeutics (formerly Entos): Iambic develops AI-driven platforms for small-molecule and biologics drug discovery. Comparable AI-first foundation model approach with enterprise pharma partnership model.
Broad incumbents
- Isomorphic Labs: Alphabet-owned commercial venture applying DeepMind's protein folding and biology foundation models to drug discovery. Represents the most direct Big Tech competitor with comparable foundation model approach and unmatched compute resources.
- NVIDIA (BioNeMo): NVIDIA's BioNeMo platform provides foundation models and tools for life science AI development. Indirect competitor as an enabling infrastructure and platform provider that competes for similar enterprise customers.
Emerging players
- Genesis Therapeutics: Genesis Therapeutics applies AI foundation models to small molecule drug discovery, with comparable enterprise pharma partnerships. More narrowly focused on small molecules versus BioMap's broader biologics + multi-vertical scope.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
BioMap social profiles
Digital presenceBioMap financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioMap leadership team
Management profileNumber of profiles
Profiles3 records
BioMap funding detail
Funding detailFunding overview
Funding rounds2 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioMap M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioMap
What does BioMap do?
BioMap builds and licenses AI foundation models and an integrated life science discovery platform (BioMap OS) powered by the proprietary 268-billion-parameter xTrimo V4 foundation model. The platform delivers a dry-wet closed-loop discovery system for protein and antibody design, novel target identification, and therapeutic discovery, with both licensing and fee-based discovery services for enterprise pharmaceutical and biotech customers.
Is BioMap a public or private company?
BioMap is a private company. It is classified as venture growth investor backed and is currently operating.
When was BioMap founded?
BioMap was founded in 2019. It employs 51 to 100 people.
Where is BioMap based?
BioMap is headquartered in Palo Alto, United States, in the North America region.
How does BioMap make money?
Two revenue lines are on record. System Licensing is the primary driver. The others are discovery Services.
Who are BioMap's main competitors?
Direct peers on record are Insitro, Recursion Pharmaceuticals, Schrödinger, Inc., Exscientia, Generate Biomedicines, AbCellera Biologics and Iambic Therapeutics (formerly Entos). Broad incumbents are Isomorphic Labs and NVIDIA (BioNeMo). Genesis Therapeutics is listed as an emerging player.
Does BioMap have an API?
No public API is recorded for BioMap.
What industry is BioMap in?
BioMap's product category is AI Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.